- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06495996
L'étude Protrieve PROTECTOR (PROTECTOR)
PROTECTOR : Évaluation de la sécurité et de l'efficacité de la gaine Protrieve dans la prévention de l'embolie pulmonaire intraprocédurale cliniquement significative en fournissant une protection embolique dans la VCI pendant les procédures de thrombectomie pour traiter la TVP
The Protrieve PROTECTOR Study is a prospective, single-arm, multicenter study of the Protrieve Sheath.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The primary study objective is to evaluate the safety and effectiveness of the Protrieve Sheath in preventing clinically significant intraprocedural pulmonary embolism by providing embolic protection in the IVC during thrombectomy procedures to treat DVT.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
California
-
Newport Beach, California, États-Unis, 92663
- Hoag Hospital
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Yale University
-
-
Florida
-
Miami, Florida, États-Unis, 33176
- Baptist Health South Florida
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46204
- IU Health Methodist Hospital
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21218
- MedStar Union Memorial Hospital
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Beth Israel Deaconess Medical Center
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89102
- University Medical Center Southern Nevada
-
-
New Jersey
-
Englewood, New Jersey, États-Unis, 07631
- Englewood Hospital
-
-
New York
-
New York, New York, États-Unis, 10016
- NYU Langone Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Allegheny General Hospital
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37203
- Vanderbilt University Medical Center
-
-
Texas
-
Galveston, Texas, États-Unis, 77555
- University of Texas Medical Branch
-
Houston, Texas, États-Unis, 77030
- University of Texas MD Anderson Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, États-Unis, 26506
- West Virginia University Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Age ≥ 18 years
-
Planned intervention for DVT presenting with one or more of the following characteristics indicative of elevated risk for PE:
- Bilateral iliofemoral DVT
- Clot extending into or located in the IVC
- In-stent thrombosis
- Presence of thrombosed IVC filter
- Other features that the investigator deems put the subject at elevated risk for thromboembolism
-
Willing and able to provide informed consent
Exclusion Criteria:
- Current symptomatic PE
- Known anatomic inability to place Protrieve device via jugular vein access site
- Presence of clot extending to the IVC-Right Atrial junction or in the SVC
- Subject is pregnant
- Severe allergy to iodinated contrast agents that cannot be mitigated
- INR > 1.7 if not currently on anticoagulation therapy, platelets < 50,000/μl which cannot be corrected prior to enrollment, or Hemoglobin < 8.0 g/dL
- Severe renal impairment in patients who are not yet on dialysis that in the Investigator's discretion would pose risk to the patient with the use of marketed contrast agents
- Subject is participating in another study that may interfere with this study
- Subject has any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject
- Subject has previously completed or withdrawn from this study
- Limb-threatening circulatory compromise (e.g., phlegmasia)
- Uncontrolled severe hypertension on repeated readings (systolic > 180mmHg or diastolic > 105mmHg)
- Severe allergy, hypersensitivity to, or thrombocytopenia from heparin
- Inability to provide therapeutic anticoagulation per Investigator discretion
- Known hypercoagulable states that, in the opinion of the Investigator, cannot be medically managed throughout the study period
- Inability to be a candidate for intervention due to medical or technical reasons based on physician judgement
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Protrieve Sheath
The Protrieve Sheath is intended for embolic protection in the inferior vena cava (IVC) to prevent clinically significant intraprocedural pulmonary embolism during mechanical thrombectomy procedures in patients with high risk of embolization. |
Percutaneous mechanical thrombectomy (PMT) is the endovascular removal of thrombus by catheter-based mechanical or aspiration methods. The term PMT generally describes interventional procedures performed without the use of lytic agents and frequently involves instrumentation in extensive amounts of fresh thrombus. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Primary Effectiveness Measure:
Délai: 24 Hours (+-12 Hours)
|
a. Clinically significant PE |
24 Hours (+-12 Hours)
|
|
Primary Safety Measure:
Délai: 24 Hours (+-12 Hours)
|
|
24 Hours (+-12 Hours)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Capture of Thromboembolic Material
Délai: 24 Hours (+-12 Hours)
|
a. Capture and removal of thromboembolic material in the Protrieve funnel, as assessed by proportion of study cases where any material was either entrapped in the funnel or removed via Protrieve |
24 Hours (+-12 Hours)
|
|
Device Success
Délai: 24 Hours (+-12 Hours)
|
b. Device success, defined as successful delivery, deployment, and retrieval of the Protrieve device without complications |
24 Hours (+-12 Hours)
|
|
Venous Access Routes
Délai: 24 Hours (+-12 Hours)
|
c. Thrombectomy via supplementary venous access routes |
24 Hours (+-12 Hours)
|
|
Estimated Percentage of the Protrieve Funnel Obstructed
Délai: 24 Hours (+-12 Hours)
|
d. Estimated percentage of the Protrieve funnel obstructed by clot, as observed by visual inspection or imaging |
24 Hours (+-12 Hours)
|
|
Blood Transfusions
Délai: 24 Hours (+-12 Hours)
|
e. Blood transfusions associated with Protrieve Sheath access site bleeding |
24 Hours (+-12 Hours)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Ripal Gandhi, MD, Baptist Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 23-003
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .